AIP
TRIB

ARS Investment Partners’s Trinity Biotech TRIB Stock Holding History

ARS Investment Partners’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,536
Closed -$399K – 166
2016
Q4 		$399K Buy
+11,536
New +$397K 0.06% 137

Other funds holding TRIB

PIM
Paradice Investment Management Denver, Colorado $532M AUM 29.6% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
SM
Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return

ARS Investment Partners's TRIB Position: Q1 2017 in Review

ARS Investment Partners sold out of Trinity Biotech (TRIB) in Q1 2017, closing a stake of 11,536 shares — an estimated $399K sold.

ARS Investment Partners first reported a position in TRIB in Q4 2016 and held it in 1 quarter. The position peaked at $399K in Q4 2016. 67 funds tracked by Wall St. Rank hold TRIB as of Q1 2017.

  • ARS Investment Partners reported no remaining Trinity Biotech position as of Q1 2017 after selling out during the quarter.
  • ARS Investment Partners sold 11,536 Trinity Biotech shares in Q1 2017, an estimated $399K.
  • ARS Investment Partners first reported a position in Trinity Biotech in Q4 2016 and held it in 1 quarter.
  • ARS Investment Partners's Trinity Biotech position peaked at $399K in Q4 2016.
  • 67 funds tracked by Wall St. Rank held Trinity Biotech as of Q1 2017.

Based on ARS Investment Partners's 13F filing for Q1 2017, filed 10 May 2017.